These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7518572)

  • 1. Inhibition by morphine of the cardiovascular and behavioral responses evoked by centrally administered substance P in conscious rats.
    Itoi K; Jost N; Tschöpe C; Culman J; Badoer E; Unger T
    Neuropharmacology; 1994 Feb; 33(2):181-7. PubMed ID: 7518572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats.
    Itoi K; Tschöpe C; Jost N; Culman J; Lebrun C; Stauss B; Unger T
    Eur J Pharmacol; 1992 Sep; 219(3):435-44. PubMed ID: 1385176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
    Picard P; Regoli D; Couture R
    Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular responses induced by intrathecal substance P in the conscious freely moving rat.
    Hasséssian H; Couture R
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):594-602. PubMed ID: 2470997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress.
    Culman J; Klee S; Ohlendorf C; Unger T
    J Pharmacol Exp Ther; 1997 Jan; 280(1):238-46. PubMed ID: 8996202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats.
    Diamant M; Kashtanov SI; Fodor M; de Wied D
    Neuroendocrinology; 1992 Nov; 56(5):750-60. PubMed ID: 1488107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxytocin pathways mediate the cardiovascular and behavioral responses to substance P in the rat brain.
    Maier T; Dai WJ; Csikós T; Jirikowski GF; Unger T; Culman J
    Hypertension; 1998 Jan; 31(1 Pt 2):480-6. PubMed ID: 9453349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
    Cellier E; Barbot L; Regoli D; Couture R
    Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance P and neurokinin A induced desensitization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors.
    Culman J; Tschöpe C; Jost N; Itoi K; Unger T
    Brain Res; 1993 Oct; 625(1):75-83. PubMed ID: 7694777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous morphine infusion (IMF) to drug-naive, conscious rats evokes bradycardic, hypotensive effects, but pressor actions are elicited after IMF to rats previously given morphine.
    Thornhill JA; Townsend C; Gregor L
    Can J Physiol Pharmacol; 1989 Mar; 67(3):213-22. PubMed ID: 2743208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central cardiovascular and behavioral effects of carboxy- and amino-terminal fragments of substance P in conscious rats.
    Tschöpe C; Jost N; Unger T; Culman J
    Brain Res; 1995 Aug; 690(1):15-24. PubMed ID: 7496802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.
    Culman J; Wiegand B; Spitznagel H; Klee S; Unger T
    Br J Pharmacol; 1995 Mar; 114(6):1310-6. PubMed ID: 7542533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig.
    Roccon A; Marchionni D; Nisato D
    Br J Pharmacol; 1996 Jul; 118(5):1095-102. PubMed ID: 8818331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in nociception, arterial blood pressure and heart rate produced by intravenous morphine in the conscious rat.
    Thurston CL; Starnes A; Randich A
    Brain Res; 1993 May; 612(1-2):70-7. PubMed ID: 8330215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further localization of cardiovascular and behavioral actions of substance P in the rat brain.
    Itoi K; Jost N; Culman J; Tschöpe C; Unger T
    Brain Res; 1994 Dec; 668(1-2):100-6. PubMed ID: 7535652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The central pressor actions of substance P are inhibited by GABA.
    Schneider B; Ganten D; Lang RE; Unger T
    Eur J Pharmacol; 1986 Nov; 131(1):31-7. PubMed ID: 2434340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in the cardiovascular responses to morphine and naloxone in spinal rats.
    Cruz SL; Rodríguez-Manzo G
    Eur J Pharmacol; 2000 May; 397(1):121-8. PubMed ID: 10844106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of the substance P-induced cardiovascular responses in the rat hypothalamus.
    Itoi K; Jost N; Badoer E; Tschöpe C; Culman J; Unger T
    Brain Res; 1991 Aug; 558(1):123-6. PubMed ID: 1718566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization.
    Prat A; Picard P; Couture R
    Br J Pharmacol; 1994 May; 112(1):250-6. PubMed ID: 7518305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.
    Randich A; Robertson JD; Willingham T
    Brain Res; 1993 Feb; 603(2):186-200. PubMed ID: 8096421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.